EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kringle Pharma's EBITDA for the
three
months ended in Mar. 2026 was 円-315.37 Mil. Kringle Pharma's Revenue for the
three
months ended in Mar. 2026 was 円18.17 Mil. Therefore, Kringle Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was -1,736.02%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kringle Pharma EBITDA Margin % Related Terms
Kringle Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kringle Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4884 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Kringle Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kringle Pharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kringle Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kringle Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kringle Pharma (TSE:4884) has a EBITDA Margin % of -1,736.02% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kringle Pharma and its competitors. According to the industry distribution chart, Kringle Pharma ranks #772 out of 944 companies in the Biotechnology industry, placing it in the top 81.8%.
Is Kringle Pharma's EBITDA Margin % too high?
Kringle Pharma's current EBITDA Margin % is -1,736.02%. Based on the distribution chart, Kringle Pharma ranks #772 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kringle Pharma has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kringle Pharma ranks #772 out of 944 companies for EBITDA Margin %. This places Kringle Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current EBITDA Margin % is -1,736.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円497.82, compared to a current price of 円318.00 — trading 36.1% below its estimated fair value. The current EBITDA Margin % is -1,736.02%. Kringle Pharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current EBITDA Margin % is -1,736.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kringle Pharma (TSE:4884) Overvalued in 2026?
Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued.
The current stock price of 円318.00 is trading 36.1% below its estimated GF Value™ of 円497.82.
GuruFocus considers Kringle Pharma to be Possible Value Trap.
Key valuation signals for TSE:4884:
EBITDA Margin %: -1,736.02%
GF Value™: 円497.82 vs. price of 円318.00 (36.1% below fair value)
No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
40GF Score
Get the complete analysis for TSE:4884
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4884 has been successfully added to your 
